title: Topical Minocycline Foam for the Treatment of Impetigo in Children: Results of a Randomized, Double-Blind, Phase 2 Study.
abstract: BACKGROUND
  Currently available treatment options for impetigo are limited by either systemic side effects (for oral therapy) or lack of ease of use (for topical ointment). A novel foam formulation of minocycline for topical use may improve convenience and treatment utilization for pediatric patients with impetigo.
  
  
  OBJECTIVE
  To evaluate the safety and efficacy of topically applied minocycline foam (FMX-102 1% and 4%) in the treatment of impetigo and to determine the optimal therapeutic active ingredient concentration.
  
  
  METHODS
  In this randomized, parallel-group, double-blind, comparative clinical trial, 32 subjects aged ≥2 years with a clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering impetigo were randomized to treatment with FMX-102 1% or 4%, twice daily for 7 days. Subjects were followed for up to 7 days post-treatment.
  
  
  RESULTS
  Clinical cure, defined as ≥80% cured lesions (fully recovered lesions, visually determined by investigators), was achieved by 57.1% and 50.0% of FMX-102 1% and 4% subjects, respectively, at the end of treatment (visit 3). Clinical success, defined as the absence of lesions, or the drying or improvement of treated lesions (decrease in size of affected area, lesion number, or both), was demonstrated in 81.3% and 78.6% of FMX-102 1% and 4% subjects, respectively, following 3 days of treatment (visit 2), in 92.3% and 100% of the respective subjects at the end of treatment, and in 100% in both groups at follow-up (visit 4). Bacteriologic success rates at the end of treatment, defined as complete pathogen eradication, were 85% and 74% in the FMX-102 1% and 4% groups, respectively. The bacteriologic success rate for MRSA infections was 100% (11/11), with no recurrences. Both FMX-102 1% and 4% were considered well tolerated and safe.
  
  
  CONCLUSIONS
  Topical minocycline foam may be a safe and effective new treatment option for impetigo in children, including those with MRSA. <br /><br /> <em>J Drugs Dermatol.</em> 2016;15(10):1238-1243.
authors.forename: Shlomo
authors.initials: S
authors.lastname: Chamny
authors.forename: Dan
authors.initials: D
authors.lastname: Miron
authors.forename: Nadia
authors.initials: N
authors.lastname: Lumelsky
authors.forename: Hana
authors.initials: H
authors.lastname: Shalev
authors.forename: Elana
authors.initials: E
authors.lastname: Gazal
authors.forename: Rita
authors.initials: R
authors.lastname: Keynan
authors.forename: Avner
authors.initials: A
authors.lastname: Shemer
authors.forename: Dov
authors.initials: D
authors.lastname: Tamarkin
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007169:Impetigo / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008911:Minocycline / Q000008:administration & dosage*; D009824:Ointments / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D009824:Ointments; D008911:Minocycline